Orexigen Eyes Earlier Resubmission Of Contrave NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The company is optimistic it can work out an agreement with FDA to re-file the obesity drug application before it has interim data from a cardiovascular outcomes trial in hand.